December 4, 2020
Celeste M. Murphy
Branch Chief
Office of Life Sciences
Division of Corporation Finance
Securities and Exchange Commission
Washington DC 20549
| Re: | MONOGRAM ORTHOPAEDICS INC | |
| Amendment 2 to Offering Statement on Form 1-A Submitted October 14, 2020 | ||
| File No. 024-11305 |
Dear Ms. Murphy:
We acknowledge receipt of the comments in the letter dated October 19, 2020 from the staff of the Division of Corporate Finance (the “Staff”) the regarding the Offering Statement of Monogram Orthopaedics, Inc. (the “Company”), which we have set out below, together with our responses.
Amendment 2 to Form 1-A filed October 14, 2020
Bonus Shares for Certain Investors, page 18
| 1. | We note your response to our prior comment 1. Please direct us to the StartEngine webpage where Monogram shares may be “reserved” so that we may evaluate your response and your compliance with the conditions listed in Rule 255(b). |
In response to the Staff’s comment, the Company has uploaded as Exhibit 13.2 screenshots of the process that investors will go through to “reserve” shares in the Company’s offering after clicking the “Reserve Now” button on the Company’s offering page (www.startengine.com/monogram).
Thank you again for the opportunity to respond to your questions to the Offering Statement of Monogram Orthopaedics, Inc. If you have additional questions or comments, please contact me at Andrewstephenson@crowdchecklaw.com.
Sincerely,
/s/ Andrew Stephenson
Andrew Stephenson
Partner
CrowdCheck Law LLP
cc: Benjamin Sexson
Chief Executive Officer
Monogram Orthopaedics, Inc.